Business Wire

VIBRANTZ-TECHNOLOGIES

19.12.2023 08:46:34 CET | Business Wire | Press release

Share
Eramet and Vibrantz Technologies Announce Long-Term Manganese Ore Supply Agreement for the Production of Manganese-Based Battery Technologies Benefiting the Electric Vehicle Market

Eramet and Vibrantz Technologies today announced a 10-year agreement whereby Eramet will supply Vibrantz with manganese ore, an essential raw material used in Vibrantz’s portfolio of manganese technologies for lithium-ion battery and other applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218880208/en/

Another significant step in both companies’ commitments to corporate social responsibility and supporting the transition to a lower emission future, the agreement builds on the 20-year Eramet-Vibrantz partnership to create a reliable pathway for Vibrantz’s manganese sulfate manufacture used in the production of electric vehicle (EV) batteries. Eramet’s manganese ore will be sourced from its Gabon mine which will undertake the Initiative for Responsible Mining Assurance’s (IRMA) audit process to align its operations with international best practices.

“This agreement confirms Eramet's ability to satisfy and win the loyalty of its customers and partners by supplying quality ore produced under responsible conditions,” said Christel Bories, Eramet Chairman and CEO. “Eramet is particularly well positioned to become a key responsible player in the battery value chain through our long-life, high-grade deposits in strategic metals, such as manganese in Gabon, lithium in Argentina at Centenario, and nickel and cobalt in Indonesia at Weda Bay.” Bories added that Eramet seeks to have all of its sites IRMA audited by 2026.

This news comes on the heels of Vibrantz’s announcement that it is constructing a pilot facility to process battery-grade high-purity manganese sulfate (HPMSM) at its Tampico, Mexico, site.

“As Vibrantz advances our commitment to becoming a sustainable and world-class specialty chemicals and materials solutions provider, we value our enduring partnership with Eramet,” said D. Michael Wilson, Vibrantz President and CEO. “This agreement allows Vibrantz to leverage both companies’ 50 years of combined expertise in manganese chemicals as we work to make environmentally friendly vehicles a growing reality for millions of consumers.” Wilson also said the company continues to receive positive market reception of its recent HPMSM capacity investments from battery producers and automotive original equipment manufacturers.

Explore Eramet’s activities here and learn more about Vibrantz’s trusted manganese technologies utilized in battery, agriculture, construction, electronics and water treatment end-use markets.

About Eramet

Eramet transforms the Earth’s mineral resources to provide sustainable and responsible solutions to the growth of the industry and to the challenges of the energy transition. Its employees are committed to this through their civic and contributory approach in all the countries where the mining and metallurgical group is present. Eramet recovers and develops metals essential to the construction of a more sustainable world. Fully committed to the era of metals, Eramet’s ambition is to become a reference for the responsible transformation of the Earth’s mineral resources for living well together.

Visit www.eramet.com.

About Vibrantz Technologies

Vibrantz is a leading global provider of specialty chemicals and materials whose purpose is to bring color, performance and vibrancy to life. Serving over 11,000 customers, our products and technologies serve a wide array of applications and make their way into myriad consumer products. With key competencies in particle engineering, glass and ceramic science and color technology, Vibrantz has leading positions in specialty mineral and chemical additives for batteries, electronic components and construction; pigments for paints and coatings, thermoset plastics and thermoplastics; and high-performance glass coatings and porcelain enamel solutions. Headquartered in Houston, Texas, the company employs approximately 5,000 people and operates 65 manufacturing sites across six continents.

Visit vibrantz.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231218880208/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye